However, recently published results from the AACR Project GENIE, which incorporated a large group of estrogen receptor positive breast cancer patients, reported that AKT1 mutant cases had comparable survival rates compared to AKT1 wild-type controls [20]. This evidence concerns the gene ESR1 and breast cancer.